SpyGlass Pharma insider reports preferred holdings

SpyGlass Pharma, Inc. insider Florence Anthony A. Jr., a 10% owner, filed a Form 3 reporting indirect holdings of multiple preferred stock series.

Rhea-AI Filing Summary

SpyGlass Pharma, Inc. insider Florence Anthony A. Jr., a 10% owner, filed a Form 3 reporting indirect holdings of multiple preferred stock series. These include Series B preferred stock convertible into 1,619,240 shares of common stock and Series A preferred stock convertible into 954,990 common shares.

All reported preferred shares automatically convert into common stock on a one-for-one basis before the closing of SpyGlass Pharma’s initial public offering. The securities are directly owned by New Enterprise Associates funds, while Anthony serves in managing roles at their general partners and disclaims beneficial ownership where he has no pecuniary interest.

Insider Trade Summary

6 transactions reported

Mixed 6 txns

Insider Florence Anthony A. Jr.

Role 10% Owner

Type	Security	Shares	Price	Value
holding	Series B Preferred Stock	--	--	--
holding	Series C-1 Preferred Stock	--	--	--
holding	Series C-2 Preferred Stock	--	--	--
holding	Series D Preferred Stock	--	--	--
holding	Series A Preferred Stock	--	--	--
holding	Series B Preferred Stock	--	--	--

Holdings After Transaction: Series B Preferred Stock — 1,619,240 contracts (Indirect, See Note 2); Series C-1 Preferred Stock — 1,370,168 contracts (Indirect, See Note 2); Series C-2 Preferred Stock — 1,370,168 contracts (Indirect, See Note 2); Series D Preferred Stock — 737,962 contracts (Indirect, See Note 2); Series A Preferred Stock — 954,990 contracts (Indirect, See Note 3); Series B Preferred Stock — 402,273 contracts (Indirect, See Note 3)

Footnotes (3)

1. F1. All shares of the preferred stock, par value $0.00001 per share, of the Issuer will automatically be converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") prior to the closing of the Issuer's initial public offering of its Common Stock.
2. F2. The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.
3. F3. The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. ("NEA Partners 16"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. ("NEA 16"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Exchange Act or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Florence Anthony A. Jr.’s Form 3 for SpyGlass Pharma (SGP) report?

The Form 3 reports indirect holdings of several preferred stock series in SpyGlass Pharma. These preferred shares are held through New Enterprise Associates funds and are convertible into common stock, establishing Anthony as a 10% owner at the time of the filing.

Which SpyGlass Pharma preferred stock series are disclosed in this Form 3?

The filing lists indirect holdings of Series A, Series B, Series C-1, Series C-2, and Series D preferred stock. Each series is convertible into SpyGlass Pharma common stock, with specific share amounts disclosed for each class in the derivative securities table.

How many SpyGlass Pharma common shares underlie the reported Series B preferred stock?

The Form 3 shows Series B preferred stock indirectly held that is convertible into 1,619,240 shares of common stock in one fund and 402,273 shares in another. These figures reflect the number of common shares underlying the preferred stock positions.

How will the SpyGlass Pharma preferred shares convert according to the Form 3?

All reported preferred shares convert automatically into common stock on a one-for-one basis. This conversion occurs before the closing of SpyGlass Pharma’s initial public offering of its common stock, aligning all these positions into the same common equity class.

What role do New Enterprise Associates funds play in this SpyGlass Pharma Form 3?

New Enterprise Associates 17 and 16 funds are the direct beneficial owners of the preferred shares. Florence Anthony A. Jr. is a manager of their general partners and disclaims beneficial ownership of portions of the securities where he has no pecuniary interest.

Does the Form 3 indicate direct or indirect ownership for Florence Anthony A. Jr.?

All reported holdings are marked as indirect ownership. The securities are held by NEA 17 and NEA 16 funds, with Anthony’s interest arising through his managerial roles at their general partners, and with disclaimers where he lacks pecuniary interest.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/05/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Florence Anthony A. Jr.

(Last) (First) (Middle)

104 5TH AVENUE

19TH FLOOR

(Street)

NEW YORK NY 10011

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
02/05/2026

3. Issuer Name and Ticker or Trading Symbol
SpyGlass Pharma, Inc. [ SGP ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series B Preferred Stock	(1)	(1)	Common Stock	1,619,240	(1)	I	See Note 2(2)
Series C-1 Preferred Stock	(1)	(1)	Common Stock	1,370,168	(1)	I	See Note 2(2)
Series C-2 Preferred Stock	(1)	(1)	Common Stock	1,370,168	(1)	I	See Note 2(2)
Series D Preferred Stock	(1)	(1)	Common Stock	737,962	(1)	I	See Note 2(2)
Series A Preferred Stock	(1)	(1)	Common Stock	954,990	(1)	I	See Note 3(3)
Series B Preferred Stock	(1)	(1)	Common Stock	402,273	(1)	I	See Note 3(3)

Explanation of Responses:

1. All shares of the preferred stock, par value $0.00001 per share, of the Issuer will automatically be converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") prior to the closing of the Issuer's initial public offering of its Common Stock.

2. The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.

3. The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. ("NEA Partners 16"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. ("NEA 16"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Exchange Act or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest.

	/s/ Zachary Bambach, attorney-in-fact	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.